Received prior lapatinib, an investigational ErbB-2 and/or an investigational EGFR dual tyrosine kinase inhibitors

Administration of any other chemotherapy, biological, immunotherapy or investigational agent within 14 days prior to receipt of study medication

Pregnant or breast-feeding women. Known CNS metastases, unless treated and without clinically significant neurological deficits

Moderately severe dry eye

Congestive heart failure, or a left ventricular ejection fraction

Myocardial infarction or active ischemic heart disease within 12 months prior to study drug administration

Previous malignancies unless free of recurrence for at least 5 years

Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer